Compare RYOJ & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYOJ | GRDX |
|---|---|---|
| Founded | 2015 | N/A |
| Country | Japan | United Kingdom |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.1M | 28.6M |
| IPO Year | 2024 | 2016 |
| Metric | RYOJ | GRDX |
|---|---|---|
| Price | $2.59 | $4.99 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 121.8K | 107.9K |
| Earning Date | 12-19-2026 | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.95 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.04 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.56 | $1.87 |
| 52 Week High | $8.10 | $6.93 |
| Indicator | RYOJ | GRDX |
|---|---|---|
| Relative Strength Index (RSI) | 41.93 | 54.68 |
| Support Level | $1.95 | $2.37 |
| Resistance Level | $2.78 | $5.04 |
| Average True Range (ATR) | 0.46 | 0.58 |
| MACD | 0.07 | 0.03 |
| Stochastic Oscillator | 17.64 | 44.09 |
rYojbaba Co Ltd is engaged in improving and restoring physical and mental health diminished by work-related stress through consulting and health services. The company provides consulting services to labor unions and companies wishing to build constructive relationships with labor unions and health services to osteopathic clinics and osteopathic beauty salons to alleviate physical ailments created by work-related stress.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.